NeOnc Prices $15M Registered Direct Offering at $4.20 to Redeem Preferred Stock
NTHI sits 24% above its 52-week low of $3.005 on light trading volume (0.1× avg).
Summary
NeOnc priced a $15 million registered direct offering at $4.20 per share, with proceeds earmarked to redeem Series A preferred stock and fund operations ahead of pivotal Phase 2a data.
Key Events · Financing and Capital Events · NTHI
-
Registered Direct Offering Priced
2,610,715 shares plus 960,715 pre-funded warrants and 3,571,430 five-year warrants at $4.20 per share, raising approximately $13.9 million net of fees.
-
Proceeds to Redeem Preferred Stock
Net proceeds will fund general corporate purposes and redeem the Series A Convertible Preferred Stock, removing a $5 million punitive financing obligation.
-
Warrant Overhang
3,571,430 warrants exercisable at $4.20 for five years, plus 960,715 pre-funded warrants at $0.0001, create potential future dilution of up to 4.53 million shares.
-
Placement Agent Terms
Roth Capital Partners and A.G.P./Alliance Global Partners receive a 7.0% cash fee ($1.05 million) plus up to $75,000 in expense reimbursement.
Analysis · NTHI · Life Sciences
NeOnc is raising approximately $13.9 million in net proceeds through a registered direct offering priced at $4.20 per share — a modest premium to the $4.07 last reported sale price on September 8, 2026. The deal includes 2.61 million shares, 960,715 pre-funded warrants, and 3.57 million five-year warrants at a $4.20 exercise price. Proceeds will fund working capital and redeem the punitive Series A Convertible Preferred Stock, which carries a $5 million obligation. Against a backdrop of a going concern warning, a $23 million H1 loss, and only $2.0 million in cash as of August 10, this capital is essential to extend the runway into the pivotal Phase 2a NEO100 data readout expected by end of 2026. The 7.0% placement agent fee and warrant overhang are standard for a distressed biotech, but the pricing above the last sale shows institutional demand despite the balance sheet stress.
How filings like this one have moved
In the 30 days to Sep 10, 2026, 29.9% of the 1988 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.12%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, NTHI was trading at $3.73 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $96.6M. The 52-week trading range was $3.01 to $12.99. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.